期刊文献+

透过肝素钠事件看美国FDA对质量缺陷药品的风险管理 被引量:6

FDA's risk management of quality-defects of drugs through reviewing heparin sodium event
原文传递
导出
摘要 药品风险管理体系存在漏洞在所难免,如何在处理不良事件的过程中通过科学的方法发现漏洞,采取纠正与预防措施弥补漏洞才是风险管理的核心所在。文中通过剖析美国FDA在肝素钠事件处理过程中采取的措施,总结FDA风险管理优势,为完善我国应对质量缺陷药品采取的风险管理措施提供建议。 The holes in drug risk management system are unavoidable.The core of risk management is how to find and patch the holes with scientific method during the processing of adverse events.Based on analysis of FDA's measures taken in heparin sodium event,this article concluded its advantage in drug risk management,and provided suggestions for strengthening Chinese drug risk management in dealing with quality-defects of drugs.
作者 刘璐 杨悦
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第20期1941-1945,共5页 Chinese Journal of New Drugs
关键词 药品风险管理 质量缺陷产品 肝素钠事件 drug risk management quality-defects of drug heparin sodium event
  • 相关文献

参考文献8

  • 1FDA. Information on adverse event reports and heparin [ EB/OL]. (2009 - 06 - 18 ). http ://www. fda. gov/Drugs/DrugSafety/Post- marketDrugSafetyInformationforPatientsandProviders/ucml 12669. htm.
  • 2FDA. Public Health Update : recall of heparin sodium for injection [ EB/OL ]. (2008 - 02 - 28 ). http ://www. fda. gov/Drugs/Drug- Safety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm 112665. htm.
  • 3FDA. Updated questions and answers on heparin sodium injection (Baxter) [ EB/OL]. (2008 -06 - 18 ). http://www, fda. gov/ Drugs/DrugSafety/PostmarketDrugSafetyln formationforPatientsand - Providers/ucm112606. htm.
  • 4FDA. FDA advises health care practitioners to switch suppliers and limit use of drug until problem identified [ EB/OL]. (2008 -02 - 11 ). http ://www. fda. gov/NewsEvents/Newsroom/PressAnnounce- ments/2008/ucm116858, htm.
  • 5FDA. Warning Letter: Changzhou SPL Company, Ltd. [ EB/OL]. ( 2008 - 04 - 21 ). http ://www. fda. gov/WarningLettersandNoti- ceofViolationLenerstoPharmaceuticalCompanies/UCM054109, pdf.
  • 6Contaminated heparin associated with adverse clinical events and activation of the contact system [ EB/OL]. (2008 -06 -05 ). ht- tp ://www. nejm. org/doi/full/10. 1056/NEJMoa0803200. html.
  • 7Oversulfated chondroitin sulfate is a contaminant in heparin associ- ated with adverse clinical events [ EB/OL ]. (2008 -04 -23 ). ht- tp://www, nature, com/nbt/journal/v26/n6/full/nbt1407, html.
  • 8USP. USP heparin information [ EB/OL ]. ( 2008 - 06 - 18 ). http :// www. usp. org/hottopics/heparin, html.

同被引文献41

  • 1王胜鹏,朱炯,张弛,王翀.中国与欧盟药品抽查检验监管对比研究[J].中国药事,2020,34(2):146-157. 被引量:18
  • 2赵健,邵蓉.浅析我国《药品管理法》对假劣药的界定[J].药学进展,2004,28(8):379-381. 被引量:20
  • 3佰易风波[J].中国医药导报,2007,4(03S):18-20. 被引量:2
  • 4张建平,杨晓林.齐二药、鱼腥草与欣弗:药品安全事件的法律思考[J].药学服务与研究,2007,7(4):241-244. 被引量:20
  • 5Baxter U S. Safety Information: Heparin Sodium Injection -Background Information[EB/OL].(2008-04-29) [2014-10- 24].http://www.baxter.com/information/safety_information/heparin_background_information.html.
  • 6FDA. Information on adverse event report and heparin [EB/OL].(2009-06-18) [2014-10-24].http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm112669.htm.
  • 7Testimony of Robert L. Parkinson Chief Executive Officer, Baxter International Before Subcommittee on Oversight and Investigations Committee on Energy and Commerce U.S. House of Representatives April [EB/OL].(2008-04-29)[2014-11-01].http://www.baxter.com/downloads/information/safety_information/heparin/RLP_opening_comments.pdf.
  • 8FDA. Warning Letter: Changzhou SPL Company ,Ltd.[EB/OL].(2008-0 4-21) [2014-11-01].http://www.fda.gov/ Warning Letter sand Notice of Violation Letters to Pharmaceutical Companies/UCM054109.Pdf.
  • 9Blossom D B, Kallen A J, Patel P R, et al Outbreak of Adverse Reactions Associated with Contaminated Heparin[J]. N Engl J Med,2008,359(25): 2674-2684.
  • 10Guerrini M, Beccati D, Shriver Z, et al.Over sulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events [J].Nature Biotechnology,2008,26:669-675.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部